Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457801 | 0.87 | L3MBTL1 (0.47) | LMNATDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1500924 | 0.85 | L3MBTL1 (0.46) | LMNATDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL6283511 | 0.81 | LMNA (0.50) | LMNATDP1ALDH1A1FDPSSMN1; SMN2 | |
| Trifluoromethanesulfonic Acid SCHEMBL9555532 | 0.81 | LMNA (0.50) | LMNATDP1ALDH1A1FDPSSMN1; SMN2 | |
| Trifluoromethanesulfonic Acid SCHEMBL693197 | 0.78 | TDP1 (0.59) | LMNATDP1ALDH1A1KMT2A | |
| Trifluoromethanesulfonic Acid SCHEMBL26104061 | 0.78 | LMNA (0.55) | LMNATDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28196672 | 0.78 | L3MBTL1 (0.49) | LMNATDP1FDPSSMN1; SMN2L3MBTL1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28211391 | 0.77 | LMNA (0.43) | LMNATDP1ALDH1A1FDPSSMN1; SMN2 | |
| Trifluoromethanesulfonic Acid SCHEMBL26103744 | 0.76 | LMNA (0.52) | LMNATDP1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL496697 | 0.76 | TDP1 (0.54) | LMNATDP1ALDH1A1FDPSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3849664-B1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3849664-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-112739420-A | Phenoxy-pyridyl-pyrimidine compounds and methods of use | 基因泰克公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020056089-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20130178472-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-11 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | disclosed |
| EP-2351745-A1 | Pyrazine derivatives and use as PI3K inhibitors | Merck Serono S.A. (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178472-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | NDUFS2, NDUFS6, NDUFS3 | LMNA 2170/4885TDP1 2992/4885ALDH1A1 949/4885 |
| US-20230057166-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | XBP1, ERN1, ESR2 | LMNA 1725/4885TDP1 68/4885ALDH1A1 2362/4885 |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | LMNA 3458/4885TDP1 605/4885ALDH1A1 1531/4885 |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | F12, F2, F11 | LMNA 621/4885TDP1 365/4885ALDH1A1 690/4885 |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | XBP1, ERN1, ESR2 | LMNA 1725/4885TDP1 68/4885ALDH1A1 2362/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | LMNA 4784/4885TDP1 1287/4885ALDH1A1 2357/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | LMNA 4784/4885TDP1 1287/4885ALDH1A1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.